Table 1 Participants characteristics
From: BMI1 is associated with CSF amyloid-β and rates of cognitive decline in Alzheimer’s disease
ADNI | ROS/MAP | ||
|---|---|---|---|
CSF dataset | ADAS-cog 13 dataset | ||
Number of subjects, n | 1157 | 1495 | 1084 |
Age, years (mean (SD)) | 73.0 (7.3) | 73.5 (7.2) | 80.5 (6.8) |
Male sex, n (%) | 509 (44.0) | 850 (56.9) | 361 (33.3) |
Education, years (mean (SD)) | 16.1 (2.8) | 16.0 (2.8) | 16.43 (3.6) |
APOE ε4 carrier, n (%) | 544 (47.0) | 709 (47.4) | 284 (26.2) |
Follow-up duration, years (mean (SD)) | – | 4.3 (3.0) | 7.5 (4.6) |
Diagnosis, n (%)a | |||
CN | 337 (29.1) | 445 (29.8) | 683 (63.0) |
MCI | 594 (51.3) | 763 (51.0) | 312 (28.8) |
Dementia | 226 (19.5) | 287 (19.2) | 89 (8.2) |
CSF Aβ42, pg/mL (mean (SD)) | 1038.8(600.9) | – | – |
ADAS-cog 13, (mean (SD)) | – | 17.0 (9.5) | – |
Global cognition composite score, (mean (SD)) | – | – | -0.125 (0.631) |
Amyloid positivity, n (positive/negative/missing) | 843/314/0 | 882/359/254 | – |